Latest Roswell Park Cancer Institute Stories
NCCN announces new updates to the NCCN Guidelines for Breast Cancer and Breast Cancer Risk Reduction Guidelines.
NCCN recently received a $4 million research grant from Wyeth Pharmaceuticals to evaluate the safety and effectiveness of temsirolimus in the treatment of solid tumors. Temsirolimus is currently approved to treat advanced renal cell carcinoma (RCC).
NCCN, in collaboration with the Abu Dhabi Health Services Company (SEHA), announce The Second Annual Middle East and North Africa NCCN Guidelines Congress scheduled for April 23 - 26, 2009 in Abu Dhabi, United Arab Emirates (UAE).
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York City, November 10-12, 2008. The conference will be held at The New York Palace Hotel.
A U.S. company says it's started initial human safety testing of a drug designed to treat exposure to radiation from nuclear weapons or a nuclear accident. Cleveland BioLabs Inc. said it dosed its first healthy volunteer this month in the human safety study required by the U.S.
Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will present at the 2008 BIO Investor Forum in San Francisco, October 29-31, 2008. The conference will be held at The Palace Hotel in San Francisco.
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on October 14, the first healthy volunteer was dosed in the initial human safety study for Protectan CBLB502, a drug under development for the treatment for Acute Radiation Syndrome (ARS).
The National Comprehensive Cancer Network (NCCN), Abraxis BioScience (NASDAQ:ABII), and AstraZeneca (NYSE:AZN) today announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anti-cancer drug ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), which is based on the company's proprietary tumor targeting technology known as the nab(TM) platform.
RALEIGH, N.C., Sept. 30 /PRNewswire/ -- The physicians and staff of Cancer Centers of North Carolina are pleased to announce the arrival of Dr. Monica Brown Jones, gynecological oncologist and surgeon. Dr.
- An armed gangster.